Skip to main content
Premium Trial:

Request an Annual Quote

Intermountain Announces Funding Opportunity for Precision Genomics Projects

NEW YORK (GenomeWeb) – Intermountain Precision Genomics this week put out a call for translational research project proposals from groups interested in leveraging its samples and high-throughput next-generation sequencing capabilities. 

Researchers across industry, academia, and non-profit institutions may apply for the opportunity to receive up to $100,000 in matched funds from Intermountain to cover costs related to procuring, preparing, and sequencing samples it has garnered.

"This opportunity can ease the financial burden of specimen collection and sequencing of the robust collection of samples stored at Intermountain's biorepository," said Tyler Barker, Intermountain Precision Genomics senior scientist, in a statement. "The Translational Science Center provides high-throughput sequencing using cutting-edge NGS technology and delivers annotated clinical data at competitive rates."

The application deadline is Aug. 1, and the funding recipients will be announced Sept. 15.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.